Warfarin (n = 101) Rivaroxaban (n = 26) Apixaban (n = 5)
χ2 (df)
p-value (Significance)
No. of patients (%) 101 (76.5) 26 (19.7) 5 (3.8)
Median age (IQR*) 71 (14) 71 (21) 70 (13) 0.169 (2) 0.919 (NS)
Gender 0.481 (2) 0.786 (NS)
Male (n, %) 48 (47.5) 14 (53.8) 2 (40.0)
Female (n, %) 53 (52.5) 12 (46.2) 3 (60.0)
Race 7.05 (6) 0.316 (NS)
Chinese (n, %) 60 (59.4) 19 (73.1) 2 (40.0)
Malay (n, %) 23 (22.8) 3 (11.5) 3 (60.0)
Indian (n, %) 8 (7.9) 1 (3.9) 0 (0)
Others (n, %) 10 (9.9) 3 (11.5) 0 (0)
Event Outcome§ 9.85 (4) 0.0431 (S)
Bleeding (n, %) 37 (36.6) 3 (11.5) 0 (0)
Thromboembolic (n, %) 8 (7.9) 5 (19.2) 1 (20.0)
Neither (n, %) 56 (55.5) 18 (69.3) 4 (80.0)
Concurrent medications (within 7 days before occurrence of bleeding) NA NA
Aspirin (n, %) 2 (2.0) 0 (0) 0 (0)
Other NSAIDs (n, %) 2 (2.0) 0 (0) 0 (0)
Clopidogrel (n, %) 1 (1.0) 0 (0) 0 (0)
Other antiplatelets (n, %) 0 (0.0) 0 (0) 0 (0)